Aurobindo Pharma has completed the acquisition of entire 80% of the equity share capital of Tergene Biotech, a step-down subsidiary of the Tergene and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the Aurobindo Pharma. The purchase consideration is of Rs 10.76 crore. Post this transaction, Tergene has become a direct subsidiary of the company.
Earlier on February 6, 2025, the company’s board had approved to purchase entire 80% of the equity share capital of Tergene Biotech.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
